Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 701 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Obesity in Diabetes Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

NCT02959762
View directory record Official record
Conditions
Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions
Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

NCT01272219
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3,731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Growing Resilience in Wind River Indian Reservation

NCT02672748
View directory record Official record
Conditions
Obesity, Overweight, Diabetes
Interventions
Garden
Other
Lead sponsor
University of Wyoming
Other
Eligibility
5 Years to 80 Years
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Laramie, Wyoming
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

NCT00823992
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Bermuda Dunes, California • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 5, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

Amlexanox for Type 2 Diabetes and Obesity

NCT01842282
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

NCT05405244
View directory record Official record
Conditions
Overweight and Obesity, Eating Behavior
Interventions
Placebo, Bromocriptine-QR
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 5, 2026, 5:09 AM EDT
Completed No phase listed Observational

Reversal of Obese/Diabetic Cardiomyopathy After Gastric Bypass Surgery

NCT01067209
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT05134662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Fort Myers, Florida • Sarasota, Florida • River Forest, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

NCT05890950
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus in Obese
Interventions
K-757 and K-833, Matching placebo to K-757 and K-833
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals

NCT01862029
View directory record Official record
Conditions
Obesity
Interventions
Roflumilast
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects

NCT01757756
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
Pf-05175157, placebo, midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects

NCT02684565
View directory record Official record
Conditions
Prediabetic State
Interventions
BCAA High Protein supplement, BCAA Low Protein supplement
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity

NCT05017571
View directory record Official record
Conditions
Obesity, Insulin Resistance, Inflammation
Interventions
Colchicine, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 5, 2026, 5:09 AM EDT
Recruiting Phase 3 Interventional

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NCT07282600
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Extended Criteria For Fetal Myelomeningocele Repair

NCT02664207
View directory record Official record
Conditions
Obesity, Myelomeningocele, Pregnancy, Diabetes Mellitus in Pregnancy, Fetal Anomaly
Interventions
Open Fetal Repair of Myelomeningocele
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiovascular Risk Factors, Body Composition, Fitness Levels And Quality Of Life In Overweight And Obese 8-17 Year Olds

NCT02024399
View directory record Official record
Conditions
Childhood Obesity, Type 2 Diabetes, Hypercholesterolemia, Hypertension
Interventions
Exercise
Other
Lead sponsor
Stony Brook University
Other
Eligibility
8 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 5, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
NNC0519-0130, Placebo, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
18
States / cities
San Dimas, California • San Ramon, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 5, 2026, 5:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects

NCT03991299
View directory record Official record
Conditions
Obese, Diabetes Mellitus, Type 2
Interventions
Botox 200 UNT Injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 5, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

NCT07783802
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
30
States / cities
Huntsville, Alabama • Tucson, Arizona • Glendora, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 5, 2026, 5:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Regulation Of Maternal Fuel Supply And Neonatal Adiposity

NCT00826904
View directory record Official record
Conditions
Fetal Macrosomia, Gestational Diabetes
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

NCT00486291
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
VI-0521, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Developing an Adaptive Lifestyle Intervention Program in Family Medicine Clinics

NCT04392284
View directory record Official record
Conditions
Insulin Resistance, Obesity, Diabetes, Hypertension, Dyslipidemias, Metabolic Syndrome
Interventions
Diet Counseling, Exercise Counseling
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 5, 2026, 5:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epigenetics and the Origin of Muscle Insulin Resistance in Humans

NCT01726491
View directory record Official record
Conditions
Diabetes Mellitus Type 2 in Obese, Obesity
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 5, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients

NCT02551640
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Prediabetic State, Hypertension, Prehypertension, Obesity
Interventions
FeatForward App (on study smartphone)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Charlestown, Massachusetts • Revere, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 5, 2026, 5:09 AM EDT